Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SCN4A | P35499 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7524247 | 1.00 | PTPN1 (0.53) | PTPN1KDM4EHSD17B10HPGDSCN4A | |
| SCHEMBL7519532 | 0.85 | PTPN1 (0.47) | PTPN1KDM4EHPGDPTPN2PTPRC | |
| SCHEMBL7513085 | 0.84 | PTPN1 (0.47) | PTPN1PTPN2PTPRCNPC1RAB9A | |
| SCHEMBL6318391 | 0.84 | KDM4E (0.52) | PTPN1KDM4EHSD17B10HPGDSCN4A | |
| SCHEMBL7520327 | 0.84 | PTPN1 (0.43) | PTPN1KDM4EHPGDPTPN2PTPRC | |
| SCHEMBL7516893 | 0.83 | PTPN1 (0.50) | PTPN1KDM4EHSD17B10HPGDSCN4A | |
| SCHEMBL7698367 | 0.83 | KDM4E (0.50) | PTPN1KDM4EHSD17B10HPGDSCN4A | |
| SCHEMBL7699527 | 0.83 | KDM4E (0.50) | PTPN1KDM4EHSD17B10HPGDSCN4A | |
| SCHEMBL7520917 | 0.82 | PTPN1 (0.42) | PTPN1HPGDPTPN2PTPRCNPC1 | |
| SCHEMBL7515936 | 0.81 | PTPN1 (0.43) | PTPN1PTPN2PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020099073-A1 | Modulators of protein tyrosine phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2002-07-25 | — | — | US | claimed |
| US-20020099073-A1 | Modulators of protein tyrosine phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099073-A1 | Modulators of protein tyrosine phosphatases (PTPases) | PTPN1, PTPRO, PTPRS | PTPN1 1/4885KDM4E 1221/4885HSD17B10 2026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.